The HER receptor family: A rich target for therapeutic developmentMASS, Robert D.International journal of radiation oncology, biology, physics. 2004, Vol 58, Num 3, pp 932-940, issn 0360-3016, 9 p.Conference Paper

Antitumor activity of HER1/GEFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft modelsJIANPING CHEN; SMITH, Melissa; KOLINSKY, Kenneth et al.Cancer chemotherapy and pharmacology. 2007, Vol 59, Num 5, pp 651-659, issn 0344-5704, 9 p.Article

Phase II Study of Erlotinib in Japanese Patients with Advanced Non-small Cell Lung CancerTAKAHASHI, Toshiaki; YAMAMOTO, Nobuyuki; SEGAWA, Yoshihiko et al.Anticancer research. 2010, Vol 30, Num 2, pp 557-563, issn 0250-7005, 7 p.Article

Erlotinib for Metastatic Non-Small-Cell Lung Cancer : First-, Second-or Third-Line Setting -Does It Matter ? A Single-Institution ExperienceAILAWADHI, Sikander; DERBY, Lyudmyla; NATARAJAN, Raj et al.Oncology. 2009, Vol 76, Num 2, pp 85-90, issn 0030-2414, 6 p.Article

Protein kinase inhibitors : Structural insights into selectivity : Target specificity of effective anticancer therapeuticsTHAIMATTAM, Ram; BANERJEE, Rahul; MIGLANI, Rajni et al.Current pharmaceutical design. 2007, Vol 13, Num 27, pp 2751-2765, issn 1381-6128, 15 p.Article

Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostaticsHUETHER, Alexander; HÖPFNER, Michael; SUTTER, Andreas P et al.Journal of hepatology. 2005, Vol 43, Num 4, pp 661-669, issn 0168-8278, 9 p.Article

Oral complications of targeted cancer therapies: A narrative literature reviewWATTERS, A. L; EPSTEIN, J. B; AGULNIK, M et al.Oral oncology (1997). 2011, Vol 47, Num 6, pp 441-448, issn 1368-8375, 8 p.Article

Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumorsYAMAMOTO, Noboru; HORIIKE, Atsushi; FUJISAKA, Yasuhito et al.Cancer chemotherapy and pharmacology. 2008, Vol 61, Num 3, pp 489-496, issn 0344-5704, 8 p.Article

EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapyHAISHENG GUO; YUNYAN WAN; GUANGYAN TIAN et al.Oncology reports. 2012, Vol 27, Num 3, pp 880-890, issn 1021-335X, 11 p.Article

Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100SMITH, N. F; BAKER, S. D; GONZALEZ, F. J et al.British journal of cancer. 2008, Vol 98, Num 10, pp 1630-1632, issn 0007-0920, 3 p.Article

A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancerMILTON, Daniel T; AZZOLI, Christopher G; MILLER, Vincent A et al.Cancer. 2006, Vol 107, Num 5, pp 1034-1041, issn 0008-543X, 8 p.Article

PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracerMEMON, A. A; WEBER, B; WINTERDAHL, M et al.British journal of cancer. 2011, Vol 105, Num 12, pp 1850-1855, issn 0007-0920, 6 p.Article

EGFR and HER-2 antagonists in breast cancerO'DONOVAN, Norma; CROWN, John.Anticancer research. 2007, Vol 27, Num 3A, pp 1285-1294, issn 0250-7005, 10 p.Conference Paper

Les inhibiteurs des récepteurs de l'Epidermal Growth Factor (EGF) = Epidermal growth factor inhibitorsDELBALDO, C; FAIVRE, S; RAYMOND, E et al.La Revue de médecine interne (Paris). 2003, Vol 24, Num 6, pp 372-383, issn 0248-8663, 12 p.Article

EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancerHUETHER, Alexander; HÖPFNER, Michael; BARADARI, Viola et al.Biochemical pharmacology. 2005, Vol 70, Num 11, pp 1568-1578, issn 0006-2952, 11 p.Article

Severe cutaneous reaction to cetuximab with possible association with the use of over-the-counter skin care products in a patient with oropharyngeal cancerWARIS, Waris; NAIK, Seeta; IDREES, Imran et al.Cutaneous and ocular toxicology (Print). 2009, Vol 28, Num 1, pp 41-44, issn 1556-9527, 4 p.Article